SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 — SUBSEQUENT EVENTS Management evaluated subsequent events and transactions that occurred after the balance sheet date, up to the date that the unaudited condensed consolidated financial statements were issued. On July 1, 2024, the Company, consummated a public offering (the “Offering”) of an aggregate of 3,000,000 shares of the Company’s Class common stock, $0.001 par value per share, resulting in aggregate gross proceeds of approximately $5,250,000. The Company filed a registration statement on Form S-1 (the “Registration Statement”) relating to the Offering (File No. 333-279684) was initially filed with U.S. Securities and Exchange Commission (the “SEC”) on May 23, 2024, as amended, and was declared effective by the SEC on June 27, 2024. On July 29, 2024, Michael Nketiah submitted his resignation as Senior Vice President of Quality, Clinical and Regulatory of the Company. Mr. Nketiah’s resignation has an effective date of August 16, 2024. He will continue to serve the Company in his current capacity until such effective date. Management did not identify any additional subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2024

NOTE 9 — SUBSEQUENT EVENTS

Management evaluated subsequent events and transactions that occurred after the balance sheet date, up to the date that the unaudited condensed consolidated financial statements were issued. On July 1, 2024, the Company, consummated a public offering (the “Offering”) of an aggregate of 3,000,000 shares of the Company’s Class common stock, $0.001 par value per share, resulting in aggregate gross proceeds of approximately $5,250,000. The Company filed a registration statement on Form S-1 (the “Registration Statement”) relating to the Offering (File No. 333-279684) was initially filed with U.S. Securities and Exchange Commission (the “SEC”) on May 23, 2024, as amended, and was declared effective by the SEC on June 27, 2024.

On July 29, 2024, Michael Nketiah submitted his resignation as Senior Vice President of Quality, Clinical and Regulatory of the Company. Mr. Nketiah’s resignation has an effective date of August 16, 2024. He will continue to serve the Company in his current capacity until such effective date.

Management did not identify any additional subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements.